Shanghai Huilun Pharmaceutical Co., Ltd.

Shanghai Huilun Pharmaceutical Co., Ltd., founded in 2004, is a leading pharmaceutical company based in China. The company is dedicated to the development, manufacturing, and marketing of APIs and finished products, with a focus on providing higher-quality generic drugs and better innovative drugs. Their product portfolio covers a wide range of categories including cardiovascular, oncology, andrology, and anesthetic drugs. In the cardiovascular segment, Shanghai Huilun Pharmaceutical Co., Ltd. offers drugs such as Ticagrelor, Rivaroxaban, and Edoxaban. In oncology, the company provides medications like Cabozantinib, Palbociclib, Ibrutinib, Azacitidine, and Levofolinic acid. Additionally, their product line includes drugs for andrology such as Silodosin and Avanafil, as well as anesthetic medication Sugammadex sodium. With a strong commitment to delivering high-quality pharmaceutical products, Shanghai Huilun Pharmaceutical Co., Ltd. presents an attractive investment opportunity in the health care and pharmaceutical industries. As of now, the company's last investment and the associated investors are not publicly disclosed, but its steady growth and focus on high-quality drug development make it a promising prospect for potential venture capital interest.